Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.
Microarray tests for ovarian cancer, colon cancer and other cancers measure the activation of the immune system in response to tumor cell development. Pre-symptomatic and early stage cancer detection improves patient prognosis and healthcare treatment options.